Comparison of Hemochron and HemoTec activated coagulation time target values during percutaneous transluminal coronary angioplasty.

[1]  C. Simpfendorfer,et al.  Is aggressive heparinization necessary for elective PTCA? , 1993, Catheterization and cardiovascular diagnosis.

[2]  C. Gaos,et al.  Activated clotting times and activated partial thromboplastin times in patients undergoing coronary angioplasty who receive bolus doses of heparin. , 1992, Catheterization and cardiovascular diagnosis.

[3]  T. Kreulen,et al.  The relationship of anticoagulation level and complications after successful percutaneous transluminal coronary angioplasty. , 1992, American heart journal.

[4]  J. J. Ferguson.  All ACTs are not created equal. , 1992, Texas Heart Institute journal.

[5]  D. Bennett,et al.  Monitoring the effect of heparin by measurement of activated clotting time during and after percutaneous transluminal coronary angioplasty. , 1990, British heart journal.

[6]  L. Klein,et al.  Adequate heparinization during PTCA: assessment using activated clotting times. , 1989, Catheterization and cardiovascular diagnosis.

[7]  T. vanderWerf.  Percutaneous transluminal coronary angioplasty , 1984 .

[8]  W. Siegenthaler,et al.  Nonoperative dilatation of coronary-artery stenosis: percutaneous transluminal coronary angioplasty. , 1979, The New England journal of medicine.

[9]  B. Bull,et al.  Heparin therapy during extracorporeal circulation. II. The use of a dose-response curve to individualize heparin and protamine dosage. , 1975, The Journal of thoracic and cardiovascular surgery.

[10]  B. Bull,et al.  Heparin therapy during extracorporeal circulation. I. Problems inherent in existing heparin protocols. , 1975, The Journal of thoracic and cardiovascular surgery.

[11]  P. Hattersley.  Activated coagulation time of whole blood. , 1966, JAMA.